196 related articles for article (PubMed ID: 25994113)
1. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
Boccardo F; Rubagotti A; Nuzzo PV; Argellati F; Savarino G; Romano P; Damonte G; Rocco M; Profumo A
Int J Cancer; 2015 Nov; 137(10):2394-402. PubMed ID: 25994113
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.
Yang J; Xiong X; Liu S; Zhu J; Luo M; Liu L; Zhao L; Qin Y; Song T; Huang C
Proteomics; 2016 Mar; 16(6):925-34. PubMed ID: 26705257
[TBL] [Abstract][Full Text] [Related]
3. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
4. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of protein biomarkers of Escherichia coli O157:H7 by matrix-assisted laser desorption ionization-time-of-flight-time-of-flight mass spectrometry and top-down proteomics.
Fagerquist CK; Garbus BR; Miller WG; Williams KE; Yee E; Bates AH; Boyle S; Harden LA; Cooley MB; Mandrell RE
Anal Chem; 2010 Apr; 82(7):2717-25. PubMed ID: 20232878
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F
J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251
[TBL] [Abstract][Full Text] [Related]
8. A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer.
Chen Z; Xu S; Su D; Liu W; Yang H; Xie S; Meng X; Lei L; Wang X
Clin Transl Oncol; 2015 Jun; 17(6):486-94. PubMed ID: 25511546
[TBL] [Abstract][Full Text] [Related]
9. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
Nanni P; Parisi D; Roda G; Casale M; Belluzzi A; Roda E; Mayer L; Roda A
Rapid Commun Mass Spectrom; 2007; 21(24):4142-8. PubMed ID: 18022963
[TBL] [Abstract][Full Text] [Related]
10. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry.
Umar A; Dalebout JC; Timmermans AM; Foekens JA; Luider TM
Proteomics; 2005 Jul; 5(10):2680-8. PubMed ID: 15892168
[TBL] [Abstract][Full Text] [Related]
11. Oral brush biopsy analysis by matrix assisted laser desorption/ionisation-time of flight mass spectrometry profiling--a pilot study.
Remmerbach TW; Maurer K; Janke S; Schellenberger W; Eschrich K; Bertolini J; Hofmann H; Rupf S
Oral Oncol; 2011 Apr; 47(4):278-81. PubMed ID: 21354855
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
13. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.
Gast MC; Zapatka M; van Tinteren H; Bontenbal M; Span PN; Tjan-Heijnen VC; Knol JC; Jimenez CR; Schellens JH; Beijnen JH
J Cancer Res Clin Oncol; 2011 Dec; 137(12):1773-83. PubMed ID: 21913038
[TBL] [Abstract][Full Text] [Related]
14. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
Zhang GQ; Du J; Pang D
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
[TBL] [Abstract][Full Text] [Related]
15. Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma.
Dekker TJ; Balluff BD; Jones EA; Schöne CD; Schmitt M; Aubele M; Kroep JR; Smit VT; Tollenaar RA; Mesker WE; Walch A; McDonnell LA
J Proteome Res; 2014 Nov; 13(11):4730-8. PubMed ID: 24762205
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
Nuzzo PV; Rubagotti A; Zinoli L; Salvi S; Boccardo S; Boccardo F
BMC Cancer; 2016 Feb; 16():95. PubMed ID: 26872609
[TBL] [Abstract][Full Text] [Related]
17. Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
Callesen AK; Mohammed S; Bunkenborg J; Kruse TA; Cold S; Mogensen O; Christensen Rd; Vach W; Jørgensen PE; Jensen ON
Rapid Commun Mass Spectrom; 2005; 19(12):1578-86. PubMed ID: 15915448
[TBL] [Abstract][Full Text] [Related]
18. Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.
Lei L; Wang XJ; Zheng ZG; Huang J; Cao WM; Chen ZH; Shao XY; Cai JF; Ye WW; Lu HY
Anat Rec (Hoboken); 2011 Jun; 294(6):941-4. PubMed ID: 21548109
[TBL] [Abstract][Full Text] [Related]
19. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
20. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.
Matsumoto K; Shimizu C; Arao T; Andoh M; Katsumata N; Kohno T; Yonemori K; Koizumi F; Yokote H; Aogi K; Tamura K; Nishio K; Fujiwara Y
J Proteome Res; 2009 Feb; 8(2):457-62. PubMed ID: 19140672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
